Drug Trial Radar · NCT07521137
Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence
Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Sano Chemicals IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis
Conditions
- Candidiasis, Vulvovaginal
Interventions
OCF001 Intravaginal GelDrug
OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.
Placebo GelDrug
Placebo (Gel formulation without OCF)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the clinical cure of OCF001 (drug product) to treat acute VVC infection following 7-day intravaginal dose of drug productTime frame: 7 days
- Evaluate the safety and local tolerability of OCF001 (drug product) intravaginal formulation in women with moderate-to-severe acute VVC.Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UAB Sexual Health Research Clinic
Birmingham, Alabama · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.